艾拉莫德在类风湿关节炎治疗中的研究_West China Medical Journal

Authors：

Corresponding author：

Keywords：

艾拉莫德; 类风湿关节炎; 临床应用

DOI：

10.7507/1002-0179.20130246

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

类风湿关节炎是一常见的以关节组织慢性炎症性病变为主要表现的全身性疾病。艾拉莫德是我国自行研发的、获得中国食品药品监督管理局批准，用于治疗成人活动性类风湿关节炎的一类新药。现就艾拉莫德的化学性质、生物活性、作用机制及其在类风湿关节炎临床治疗中的应用进行阐述，并对艾拉莫德未来用途进行展望。

Citation： 郝春芳,刘毅,赵毅. 艾拉莫德在类风湿关节炎治疗中的研究. West China Medical Journal, 2013, 28(5): 795-798. doi: 10.7507/1002-0179.20130246 Copy

1.	焦志军, 王文红, 李晶, 等. 类风湿关节炎患者外周血单个核细胞Notch及其配体表达[J]. 现代免疫学, 2007, 27(6): 477-480.
2.	宋明侠, 王杏林, 王春龙. 艾拉莫德速释片的溶出度测定方法研究[J]. 天津药学, 2006, 18(1): 22-23.
3.	Aikawa Y, Tanuma N, Shin T, et al. A new antirheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis[J]. J Neuroimm, 1998, 89(1-2): 35-42.
4.	Jiang Y, Yu SQ. The role of nuclear transcription factor-κB pathway in acute lung injury induced by endotoxin[J]. Chin J Crit Care Med, 2004, 24: 902-904.
5.	Sawada T, Hashimoto S, Tohma S, et al. Inhibition of l-leucine methyl ester mediated killing of THP-1, a human monocytic cell line, by a new anti-inflammatory drug, T614[J]. Immunopharmacology, 2000, 49(3): 285-294.
6.	张静, 袁玉, 李健华, 等. 艾拉莫德片在中国健康志愿者体内的药动学[J]. 中国临床药学杂志, 2007, 16(4): 234-237.
7.	陈思曾, 郭永刚. 艾拉莫德、吡咯烷二硫代氨基甲酸盐单用和联合治疗恶病质[J]. 中华实验外科杂志, 2011, 28(5): 720-722.
8.	Tanaka K, Urata1 N, Mikami M, et al. Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice[J]. Inflamm Res, 2007, 56 (1) : 17-23.
9.	KeiferJ, Guttridge DC, Ashburner BP, et al. Inhibition of NF-kappa B activity by Thalidomide through Suppression of Ikappa B kinase Activity[J]. Biol Chem, 2001, 276(25): 22382-22387.
10.	高晶, 只德广, 曾勇, 等. 艾拉莫德(T-614)的临床前药代动力学研究[J]. 药物评价研究, 2009, 32 (1): 19-28.
11.	Du F, Lü LJ , Fu Q , et al. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis[J]. Arthritis Res Ther, 2008, 10(6):1-11 .
12.	Hara M , Abe T, Sugawara S, et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study[J]. Mod Rheumatol, 2007, 17(1) : 1-9.
13.	Ishiguro N, Yamamoto K, Katayama K, et al. Iguratimod-Clinical Study Group Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial[J]. Mod Rheumatol, 2012, [Epub ahead of print].
14.	Mitchell JA, Akaraserenont P, Thiemermann C, et al. Selectivity of non-steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase[J]. Proc Natl Acad Sci USA,1993, 90(24): 11693-11697.
15.	Tanaka K , Yamamoto T , Aikawa Y , et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice[J]. Rheumatol, 2003, 42(11): 1365-1371.
16.	Du F , Lü LJ , Teng JL , et al. T-614 alters the production of matrix metalloproteinases (MMP-1 and MMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro[J]. Int Immunopharmacol, 2012, 13(1): 54-60.
17.	Kawakami A, Tsuboi M, Urayama S, et a1. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells[J]. J Lab Clin Med, 1999, 133(6): 566-574.
18.	李秋霞, 古洁若. 艾拉莫德对小鼠成纤维细胞分泌胶原的影响[J]. 医学研究杂志, 2009, 38(10): 44-47.
19.	舒强, 李兴福, 刘花香, 等. 类风湿关节炎滑膜成纤维样细胞增殖特性的体外研究[J].山东大学学报·医学版, 2006, 44(11): 1095-1099.
20.	舒强, 李兴福, 侯怀水, 等. 艾拉莫德对骨关节炎滑膜成纤维样细胞特性的影响[J]. 中华风湿病学杂志, 2006, 10(7): 389-392.
21.	Malviya A, Kuiper JH , Makwana N, et al. The effect of newer anti-rheumatic drug on osteogenic cell proliferation an in-vitro study [J]. J Orthop surg Res, 2009, 4(17): 1-7.
22.	Kuriyama K, Higuchi C, Tanaka K, et al . A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein -2-induced bone formation in vivo[J]. Biochem Biophys Res Commun, 2002, 299(5): 903-909.
23.	魏伟, 张玲玲, 肖峰, 等. 艾拉莫德治疗类风湿关节炎Ⅱ期临床试验[C]. 第十二次全国临床药理学学术会议论文集, 武汉, 2010. 北京: 中国药理学会. 2010.
24.	滕佳临,吕良敬,鲍春德,等. 艾拉莫德治疗类风湿关节炎多中心随机双盲安慰剂对照研究[J].中华风湿病杂志, 2007, 11(8): 461-465.
25.	Sullivan S. Iguratimod: novel DMARD promising for rheumatoid artlritis[J]. Inpharma, 2004, 1450(1): 7.
26.	Hara M, Abe T, Sugawara S, et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis[J]. Mod rheumatol, 2007, 17(1): 10-16 .

1. 　焦志军, 王文红, 李晶, 等. 类风湿关节炎患者外周血单个核细胞Notch及其配体表达[J]. 现代免疫学, 2007, 27(6): 477-480.
2. 　宋明侠, 王杏林, 王春龙. 艾拉莫德速释片的溶出度测定方法研究[J]. 天津药学, 2006, 18(1): 22-23.
3. 　Aikawa Y, Tanuma N, Shin T, et al. A new antirheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis[J]. J Neuroimm, 1998, 89(1-2): 35-42.
4. 　Jiang Y, Yu SQ. The role of nuclear transcription factor-κB pathway in acute lung injury induced by endotoxin[J]. Chin J Crit Care Med, 2004, 24: 902-904.
5. 　Sawada T, Hashimoto S, Tohma S, et al. Inhibition of l-leucine methyl ester mediated killing of THP-1, a human monocytic cell line, by a new anti-inflammatory drug, T614[J]. Immunopharmacology, 2000, 49(3): 285-294.
6. 　张静, 袁玉, 李健华, 等. 艾拉莫德片在中国健康志愿者体内的药动学[J]. 中国临床药学杂志, 2007, 16(4): 234-237.
7. 　陈思曾, 郭永刚. 艾拉莫德、吡咯烷二硫代氨基甲酸盐单用和联合治疗恶病质[J]. 中华实验外科杂志, 2011, 28(5): 720-722.
8. 　Tanaka K, Urata1 N, Mikami M, et al. Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice[J]. Inflamm Res, 2007, 56 (1) : 17-23.
9. 　KeiferJ, Guttridge DC, Ashburner BP, et al. Inhibition of NF-kappa B activity by Thalidomide through Suppression of Ikappa B kinase Activity[J]. Biol Chem, 2001, 276(25): 22382-22387.
10. 　高晶, 只德广, 曾勇, 等. 艾拉莫德(T-614)的临床前药代动力学研究[J]. 药物评价研究, 2009, 32 (1): 19-28.
11. 　Du F, Lü LJ , Fu Q , et al. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis[J]. Arthritis Res Ther, 2008, 10(6):1-11 .
12. 　Hara M , Abe T, Sugawara S, et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study[J]. Mod Rheumatol, 2007, 17(1) : 1-9.
13. 　Ishiguro N, Yamamoto K, Katayama K, et al. Iguratimod-Clinical Study Group Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial[J]. Mod Rheumatol, 2012, [Epub ahead of print].
14. 　Mitchell JA, Akaraserenont P, Thiemermann C, et al. Selectivity of non-steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase[J]. Proc Natl Acad Sci USA,1993, 90(24): 11693-11697.
15. 　Tanaka K , Yamamoto T , Aikawa Y , et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice[J]. Rheumatol, 2003, 42(11): 1365-1371.
16. 　Du F , Lü LJ , Teng JL , et al. T-614 alters the production of matrix metalloproteinases (MMP-1 and MMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro[J]. Int Immunopharmacol, 2012, 13(1): 54-60.
17. 　Kawakami A, Tsuboi M, Urayama S, et a1. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells[J]. J Lab Clin Med, 1999, 133(6): 566-574.
18. 　李秋霞, 古洁若. 艾拉莫德对小鼠成纤维细胞分泌胶原的影响[J]. 医学研究杂志, 2009, 38(10): 44-47.
19. 　舒强, 李兴福, 刘花香, 等. 类风湿关节炎滑膜成纤维样细胞增殖特性的体外研究[J].山东大学学报·医学版, 2006, 44(11): 1095-1099.
20. 　舒强, 李兴福, 侯怀水, 等. 艾拉莫德对骨关节炎滑膜成纤维样细胞特性的影响[J]. 中华风湿病学杂志, 2006, 10(7): 389-392.
21. 　Malviya A, Kuiper JH , Makwana N, et al. The effect of newer anti-rheumatic drug on osteogenic cell proliferation an in-vitro study [J]. J Orthop surg Res, 2009, 4(17): 1-7.
22. 　Kuriyama K, Higuchi C, Tanaka K, et al . A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein -2-induced bone formation in vivo[J]. Biochem Biophys Res Commun, 2002, 299(5): 903-909.
23. 　魏伟, 张玲玲, 肖峰, 等. 艾拉莫德治疗类风湿关节炎Ⅱ期临床试验[C]. 第十二次全国临床药理学学术会议论文集, 武汉, 2010. 北京: 中国药理学会. 2010.
24. 　滕佳临,吕良敬,鲍春德,等. 艾拉莫德治疗类风湿关节炎多中心随机双盲安慰剂对照研究[J].中华风湿病杂志, 2007, 11(8): 461-465.
25. 　Sullivan S. Iguratimod: novel DMARD promising for rheumatoid artlritis[J]. Inpharma, 2004, 1450(1): 7.
26. 　Hara M, Abe T, Sugawara S, et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis[J]. Mod rheumatol, 2007, 17(1): 10-16 .

Previous Article
阻塞性睡眠呼吸暂停低通气综合征与2型糖尿病的关系
Next Article
原钙粘蛋白15在NK/T细胞淋巴瘤诊断中的价值

West China Medical Journal

艾拉莫德在类风湿关节炎治疗中的研究

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content